Navigation Links
Masimo Reports Fourth Quarter and Full Year 2010 Financial Results; Provides 2011 Guidance

IRVINE, Calif., Feb. 15, 2011 /PRNewswire/ -- Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and year ended January 1, 2011.

Masimo's total revenue for the fourth quarter rose 14.0% to $105.6 million, compared to $92.6 million for the fourth quarter of 2009.  Masimo's fourth quarter product revenue rose 16.6% to $93.8 million, compared to $80.5 million for the fourth quarter of 2009.  Revenue from Masimo rainbow products rose 44.4% to $8.4 million in the fourth quarter, compared to $5.8 million for the fourth quarter of 2009.  

Net income for the fourth quarter was $16.1 million, or $0.26 per diluted share, including $0.02 per diluted share in one-time marketing and other related expenses that Masimo had previously planned and announced after receiving $30.8 million in proceeds in 2010 from an antitrust lawsuit against Covidien.  Excluding these one-time marketing and other related expenses, adjusted net income for the fourth quarter was $17.5 million, or $0.29 per diluted share, compared to net income of $14.1 million, or $0.23 per diluted share, in the fourth quarter of 2009.  Due to rounding, the impact of excluding $0.02 per diluted share in one-time marketing and other related expenses added $0.03 per diluted share to the adjusted earnings per share calculation in the fourth quarter of 2010.

For 2010, Masimo's total revenue rose 16.1% to $405.4 million, compared to $349.1 million for 2009.  The company's product revenue rose 18.8% in 2010 to $356.4 million, compared to $300.1 million in 2009.  Revenue from Masimo rainbow products rose 69.0% to $32.9 million in 2010, compared to $19.5 million in 2009.  

Masimo's net income for 2010 was $73.5 million, or $1.21 per diluted share, including $0.18 per diluted share from the net of a one-time gain related to the $30.8 million in antitrust proceeds from Covidien and offset by $14.7 million in marketing and other related expenses that Masimo had previously planned and announced after receiving the proceeds.  Excluding these one-time items, adjusted net income for 2010 was $62.5 million, or $1.03 per diluted share, compared to net income of $53.2 million, or $0.88 per diluted share, in 2009.

During the fourth quarter, the company shipped approximately 41,800 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 37.5% compared to approximately 30,400 in the same prior year period.  For 2010, Masimo shipped approximately 153,200 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 37.5% compared to approximately 111,400 in 2009.  Masimo estimates its worldwide installed base as of January 1, 2011 to be 855,000 units, up 18.0% from 724,000 units as of January 2, 2010.Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, "Our strong fourth quarter and fiscal 2010 performance was driven by increasing global demand for our breakthrough Masimo SET and Masimo rainbow SET technologies, allowing us to advance our mission to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications."As of January 1, 2011, cash, cash equivalents and short-term investments totaled $88.3 million, compared to $189.0 million as of January 2, 2010.  The decline was due primarily to special dividend payments of $117.5 million and $44.5 million, made on March 31, 2010 and December 21, 2010, respectively.  Total 2010 dividend payments of $162.0 million were partially offset by the net proceeds from the Covidien antitrust lawsuit and operating cash flow during the year.2011 Financial Guidance Masimo expects fiscal 2011 total revenue to be between $446 million and $463 million, including product revenue in the range of $415 million to $430 million, and royalty revenue in the range of $31 million and $33 million. Included within these product revenue ranges are 2011 rainbow revenue expectations of $40 million to $50 million.  As a result, the company expects fiscal 2011 GAAP earnings per share to be between $1.17 and $1.25.  Each of the components of Masimo's guidance set forth above is an estimate only and actual performance could differ.  

Conference Call Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results.  The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 679-9937 for international callers. The reservation code for both dial-in numbers is 38781834. After the live webcast, the call will be available on Masimo's website through March 15, 2011. In addition, a telephonic replay of the call will be available through March 1, 2011. The replay dial-in numbers are (800) 642-1687 for domestic callers and +1 (706) 645-9291 for international callers. Please use reservation code 38781834.

About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at

Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies; and expectations for total revenue, royalty revenue and product revenue, including rainbow revenue, and GAAP earnings per share for the full fiscal year 2011.  These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), which you may obtain for free on the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor Contact: Sheree AronsonMedia Contact: Dana BanksVice President, Investor Relations, Masimo CorporationManager, Public Relations, Masimo Corporation (949) 297-7043 (949) 297-7348 saronson@masimo.comdbanks@masimo.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care...  by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.

MASIMO CORPORATION CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) January 1,January 2,20112010ASSETSCurrent assetsCash and cash equivalents

32,054Short-term investments

—56,989Accounts receivable, net of allowance for doubtful accounts

49,69438,897Royalties receivable


45,02831,559Prepaid expenses

4,5353,742Prepaid income taxes

3,3521,705Deferred tax assets

12,55511,585Other current assets

2,1361,357Total current assets

217,605289,388Deferred cost of goods sold

47,18428,163Property and equipment, net

15,95111,682Intangible assets, net


448448Deferred tax assets

12,56011,500Other assets

5,9905,335Total assets

356,345LIABILITIES AND EQUITYCurrent liabilitiesAccounts payable

,716Accrued compensation

21,07417,793Accrued liabilities

9,8329,754Income taxes payable

722477Deferred revenue

16,36914,641Current portion of capital lease obligation

5060Total current liabilities

70,19759,441Deferred revenue

1,554270Capital lease obligation, less current portion

122171Other liabilities

8,3236,775Total liabilities

80,19666,657EquityMasimo Corporation stockholders' equity:Common stock

5958Treasury stock

(1,209)(1,209)Additional paid-in capital

222,206195,690Accumulated other comprehensive income

92563Retained earnings

5,66494,112Total Masimo Corporation stockholders' equity

227,645288,714Noncontrolling interest

2,394974Total equity

230,039289,688Total liabilities and equity

356,345MASIMO CORPORATION CONSOLIDATED STATEMENTS OF INCOME (unaudited, in thousands, except per share information)Three Months EndedTwelve Months EndedJanuary 1,January 2,January 1,January 2,2011201020112010Revenue:Product


11,79912,16048,98548,972Total revenue

105,57492,613405,407349,115Cost of goods sold

31,44626,796119,825100,313Gross profit

74,12865,817285,582248,802Operating expenses:Selling, general and administrative

44,22735,455174,089134,577Research and development

8,3128,94036,00031,701Antitrust litigation expense (proceeds)

—70(30,728)298Total operating expenses

52,53944,465179,361166,576Operating income

21,58921,352106,22182,226Non-operating income (expense)

154(422)1,348(46)Income before provision for income taxes

21,74320,930107,56982,180Provision for income taxes

5,1126,74434,16428,158Net income including noncontrolling interests

16,63114,18673,40554,022Net (income) loss attributable to noncontrolling interests

(517)(126)125(794)Net income attributable to Masimo Corporation

53,228Net income per share attributable to MasimoCorporation stockholders:Basic


.88Weighted average shares used in per share calculations: Basic


60,83960,28960,60960,171Cash dividend declared per share

8212;The following table presents the total share-based compensation expense that is included in each functional line item of the consolidated statements of income (in thousands):Three Months EndedTwelve Months EndedJanuary 1,January 2,January 1,January 2,2011201020112010Cost of goods sold

413Selling, general and administrative

2,5191,9689,0337,720Research and development


,674MASIMO CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited, in thousands) Year endedYear endedJanuary 1,January 2,20112010Cash flows from operating activities:Net income including noncontrolling interests

54,022Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:Depreciation and amortization

6,5845,979Share-based compensation

12,30310,674Loss on disposal of property and equipment

—5Provision for doubtful accounts

108733Provision for obsolete inventory

619232Provision for warranty costs

2,3552,220Benefit from deferred income taxes

(2,231)(3,566)Income tax benefit from exercise of stock options granted prior to January 1, 2006

4,8512,758Excess tax benefits from share-based compensation arrangements

(707)(215)Changes in operating assets and liabilities:Increase in accounts receivable

(10,905)(8,982)Increase in royalties receivable

(500)(125)Increase in inventories

(14,088)(3,929)(Increase) decrease in deferred cost of goods sold

(19,080)309(Increase) decrease in prepaid expenses

(743)197Increase in prepaid income taxes

(1,648)(833)Increase in other assets

(1,396)(3,080)Increase in accounts payable

5,474777Increase in accrued compensation

3,2191,926Increase (decrease) in accrued liabilities

(2,281)1,935Increase (decrease) in income taxes payable

940(10,169)Increase (decrease) in deferred revenue

3,012(2,518)Increase (decrease) in other liabilities

1,729(1,244)Net cash provided by operating activities

61,02047,106Cash flows from investing activities:Purchase of short-term investments

(75,986)(56,989)Proceeds from sale and maturities of short-term investments

132,975—Purchases of property and equipment

(9,561)(3,636)Increase in intangible assets

(1,937)(1,851)Cash paid for acquisitions

—(1,981)Net cash provided by (used in) investing activities

45,491(64,457)Cash flows from financing activities:Repayments on long-term debt

(60)(450)Proceeds from issuance of common stock

10,2392,575Excess tax benefits from share-based compensation arrangements

707215Dividends paid

(161,978)—Net cash provided by (used in) financing activities

(151,092)2,340Effect of foreign currency exchange rates on cash

832155Net decrease in cash and cash equivalents

(43,749)(14,856)Cash and cash equivalents at beginning of period

132,054146,910Cash and cash equivalents at end of period


SOURCE Masimo Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring
2. Welch Allyn Establishes Strategic Partnership to Incorporate Masimo rainbow® SET Noninvasive Measurement Capabilities in Next-Generation Patient Monitors
3. New Published Study Finds Noninvasive Masimo PVI Accurately Predicts Fluid Responsiveness in Intensive Care Patients
4. Masimo to Report Fourth Quarter and Full Year 2010 Financial Results After Market Close on February 15, 2011
5. Masimo to Present at 29th Annual J.P. Morgan Healthcare Conference
6. New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment
7. Masimo to Present at Piper Jaffray 22nd Annual Healthcare Conference
8. Prime Healthcare Converts System-Wide to Masimo rainbow SET Technology
9. BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States
10. Masimo to Present at Lazard Capital Markets 7th Annual Healthcare Conference
11. Masimo Reports Third Quarter 2010 Financial Results
Post Your Comments:
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
Breaking Medicine News(10 mins):